• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT WITH IMMUNOVENIN IN DISIMMUNOGLOBULINEMIA DUE TO THE REACTIVATION OF CHRONIC HERPESVIRUS INFECTION IN WOMEN IN THE SECOND TRIMESTER OF PREGNANCY

METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT WITH IMMUNOVENIN IN DISIMMUNOGLOBULINEMIA DUE TO THE REACTIVATION OF CHRONIC HERPESVIRUS INFECTION IN WOMEN IN THE SECOND TRIMESTER OF PREGNANCY

机译：预测在孕妇第二胎的慢性疱疹病毒感染中激活的免疫球蛋白在双球蛋白血症中的治疗效果的方法

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to obstetrics, and relates to a method for predicting the efficacy of treatment with immunovenin in disimmunoglobulinemia due to the reactivation of chronic herpesvirus infection in women in the second trimester of pregnancy. Method comprises: in blood serum before the treatment with immunovenin, IgM and IgG antibodies to the herpes simplex virus (HSV 1 and 2 types) and to the cytomegalovirus (CMV) with the avidity index of IgG to HSV and CMV are more than 65 % in points (1 point – IgM and IgG to HSV 1 type, IgG to HSV type 2; 2 points – IgM and IgG to HSV type 1, as well as IgM and IgG to HSV type 2; 3 points – IgM and IgG to HSV type 1, IgM and IgG to HSV type 2, and IgG to CMV) (A); serum IgG level (mg/l) (B); concentration of C-reactive protein (CRP) (mg/l) (C); frequency of development of acute respiratory viral infections (ARI) during the year in points (1 point - ARVI 1-2 times a year; 2 points – SARS 3-4 times a year; 3 points – SARS 5 times or more per year) (E), and then with the help of the discriminant equation, including the determined indicators, predict the effectiveness of immunovenin treatment of disimmunoglobulinemia:D=-2.333×A-1.514×B-0.492×C-3.533×E, where D is a discriminant function with a boundary value of – 25.00. If D is less than the limiting value of the discriminant function, ineffective treatment with immunovenin of disimmunoglobulinemia is predicted, and at D equal to or greater than the limiting value, an effective treatment with immunovenin of disimmunoglobulinemia due to the reactivation of chronic herpesvirus infection in women in the second trimester of pregnancy is predicted. Probability of a correct forecast is 86.2 %.;EFFECT: invention provides a prognosis of the effectiveness of treatment with immunovenin of disimmunoglobulinemia in women with the reactivation of chronic herpesvirus infection in the second trimester of pregnancy.;1 cl
机译：发明领域本发明涉及医学，即涉及产科，并且涉及预测在妊娠中期妇女中由于慢性疱疹病毒感染的再激活而引起的免疫球蛋白对去免疫球蛋白血症的治疗效果的方法。方法包括：在用免疫静脉蛋白治疗的血清中，抗单纯疱疹病毒（HSV 1和2型）和抗巨细胞病毒（CMV）的IgM和IgG抗体，IgG对HSV和CMV的亲和力指数均超过65％以点数计（1点– IgM和IgG对应HSV 1型; IgG – HSg 2型;以及2点– IgM和IgG对应HSV 1型;以及IgM和IgG对应HSV 2型; 3点– IgM和IgG对应HSV 1型，IgM和IgG至HSV 2型，以及IgG至CMV）（A）;血清IgG水平（mg / l）（B）; C反应蛋白（CRP）的浓度（mg / l）（C）;一年中急性呼吸道病毒感染（ARI）发生的频率，以点为单位（1分-ARVI每年1-2次; 2分– SARS每年3-4次; 3分– SARS每年5次或更多） （E），然后借助包含确定的指标的判别方程，预测免疫静脉蛋白治疗双免疫球蛋白血症的有效性：D = -2.333×A-1.514×B-0.492×C-3.533×E，其中D为边界值为– 25.00的判别函数。如果D小于判别功能的极限值，则预示着用免疫球蛋白的免疫球蛋白血症的无效治疗，而当D等于或大于极限值时，则是由于慢性疱疹病毒感染的重新激活而导致的免疫球蛋白的免疫蛋白的有效治疗。预计孕妇会在妊娠中期。正确预测的可能性为86.2％。效果：本发明提供了在怀孕中期重新激活慢性疱疹病毒感染的妇女中使用去免疫球蛋白血免疫球蛋白治疗妇女的有效性的预后; 1 cl

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号